Gamco Investors INC. ET AL increased its position in shares of NxStage Medical, Inc. (NASDAQ:NXTM) by 10.2% during the fourth quarter, Holdings Channel reports. The institutional investor owned 24,403 shares of the medical device company’s stock after purchasing an additional 2,250 shares during the period. Gamco Investors INC. ET AL’s holdings in NxStage Medical were worth $591,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of NXTM. Cowen Inc. bought a new position in NxStage Medical during the third quarter worth $1,908,000. Gabelli Funds LLC bought a new position in NxStage Medical during the third quarter worth $4,941,000. JPMorgan Chase & Co. boosted its position in NxStage Medical by 239,738.6% during the third quarter. JPMorgan Chase & Co. now owns 1,870,741 shares of the medical device company’s stock worth $51,502,000 after purchasing an additional 1,869,961 shares during the period. ARP Americas LLC bought a new position in NxStage Medical during the third quarter worth $11,219,000. Finally, Bank of Montreal Can boosted its position in NxStage Medical by 15.5% during the fourth quarter. Bank of Montreal Can now owns 572,868 shares of the medical device company’s stock worth $13,880,000 after purchasing an additional 77,082 shares during the period. Institutional investors and hedge funds own 84.37% of the company’s stock.

A number of equities analysts have commented on NXTM shares. ValuEngine cut shares of NxStage Medical from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. Zacks Investment Research cut shares of NxStage Medical from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. Northland Securities reaffirmed a “hold” rating and set a $30.00 price objective on shares of NxStage Medical in a research report on Wednesday, November 8th. BidaskClub raised shares of NxStage Medical from a “strong sell” rating to a “sell” rating in a research report on Monday, February 5th. Finally, Canaccord Genuity reissued a “hold” rating and issued a $30.00 target price on shares of NxStage Medical in a research report on Tuesday, October 17th. Three equities research analysts have rated the stock with a sell rating and eight have issued a hold rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $30.25.

In other news, SVP Winifred L. Swan sold 3,500 shares of the business’s stock in a transaction dated Wednesday, December 20th. The shares were sold at an average price of $25.35, for a total value of $88,725.00. Following the completion of the sale, the senior vice president now owns 14,270 shares of the company’s stock, valued at $361,744.50. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 4.70% of the company’s stock.

Shares of NxStage Medical, Inc. (NASDAQ:NXTM) opened at $23.01 on Wednesday. NxStage Medical, Inc. has a 52-week low of $20.45 and a 52-week high of $30.80.

COPYRIGHT VIOLATION NOTICE: “NxStage Medical, Inc. (NXTM) Position Boosted by Gamco Investors INC. ET AL” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://www.thecerbatgem.com/2018/02/14/nxstage-medical-inc-nxtm-position-boosted-by-gamco-investors-inc-et-al.html.

About NxStage Medical

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Want to see what other hedge funds are holding NXTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NxStage Medical, Inc. (NASDAQ:NXTM).

Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.